Sanabolicum — Competitive Intelligence Brief

Sanabolicum (NANDROLONE CYCLOTATE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Androgen. Area: Other.

phase 2 Androgen Other Small molecule

Target snapshot

Sanabolicum (NANDROLONE CYCLOTATE). Sanabolicum works by binding to androgen receptors in the body, which can influence the development and maintenance of male characteristics.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Sanabolicum TARGET	NANDROLONE CYCLOTATE		phase 2	Androgen
Talazoparib with enzalutamide	talazoparib-with-enzalutamide	Pfizer	marketed	PARP inhibitor and androgen receptor inhibitor	PARP enzymes and androgen receptor	Not yet launched
Winlevi	CLASCOTERONE	Sun Pharma	marketed	Androgen Receptor Inhibitor [EPC]	Androgen receptor	2020-01-01
Aveed	TESTOSTERONE UNDECANOATE	Marius	marketed	Androgen	Androgen receptor	2014-01-01
Xtandi	enzalutamide	Astellas Pharma	marketed	Androgen Receptor Inhibitor [EPC]	Androgen receptor	2012-01-01
Xtandi	xtandi	Astellas Pharma	marketed	Androgen receptor inhibitor	Androgen receptor	2012-01-01
Abiraterone Acetate	abiraterone	Pfizer	marketed	Androgen biosynthesis inhibitor	CYP17	2011-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2026-08-24 — Xtandi · 8183274 · US
• 2027-08-13 — Xtandi · 7709517 · US

Sponsor landscape (Androgen class)

1. · 4 drugs in this class
2. Azurity · 1 drug in this class
3. Endo · 1 drug in this class
4. Marius · 1 drug in this class
5. Merck & Co. · 1 drug in this class
6. The Affiliated Hospital of Qingdao University · 1 drug in this class
7. Woodward Specl · 1 drug in this class